Rosiglitazone

Updated: 2026-09-19

Overview

Rosiglitazone is a thiazolidinedione-class antidiabetic agent developed to manage type 2 diabetes mellitus. It functions as a selective agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), enhancing insulin sensitivity in adipose tissue, skeletal muscle, and the liver. Marketed under the brand name Avandia, it was first approved by the FDA in 1999 but later faced restrictions due to cardiovascular safety concerns. Despite regulatory challenges, rosiglitazone remains clinically significant in certain patient populations where benefits outweigh risks. It is typically prescribed as adjunct therapy when other antidiabetic medications fail to achieve glycemic control. The drug's mechanism involves reducing insulin resistance rather than stimulating insulin secretion.

Physical and Chemical Properties

Rosiglitazone is a white to off-white crystalline powder with a molecular weight of 357.43 g/mol. Its chemical structure includes a thiazolidinedione ring, which is essential for PPAR-γ binding activity. The compound has a melting point range of 153-155°C and demonstrates slight solubility in water but better solubility in organic solvents like ethanol and dimethyl sulfoxide (DMSO). The drug exhibits stability under recommended storage conditions but is sensitive to light and moisture. Its stability profile necessitates protective packaging, typically aluminum foil blisters or amber glass containers. Analytical methods for quality control include HPLC and spectrophotometry to ensure purity and potency.

Main Applications

Rosiglitazone is primarily used to improve glycemic control in adults with type 2 diabetes mellitus, particularly those with significant insulin resistance. It is often combined with metformin or sulfonylureas when monotherapy proves insufficient. The drug reduces HbA1c levels by 1-1.5% on average, with effects noticeable within weeks of treatment initiation. In some regions, rosiglitazone is also investigated for off-label uses such as polycystic ovary syndrome (PCOS) due to its insulin-sensitizing properties. However, its use is strictly regulated in many countries, requiring thorough cardiovascular risk assessment before prescription. Clinical guidelines emphasize regular monitoring for adverse effects during therapy.

Safety and Storage

Rosiglitazone carries a black box warning for increased risk of heart failure and cardiovascular events. It is contraindicated in patients with NYHA Class III/IV cardiac failure and requires caution in those with edema or pre-existing heart disease. Other risks include weight gain, fractures (particularly in women), and potential liver enzyme elevations. Proper storage involves maintaining the drug at 2-8°C in original packaging to prevent degradation. Bulk pharmaceutical material should be stored in sealed containers with desiccants under inert gas when necessary. Stability studies indicate a shelf life of 24-36 months when stored correctly, though repackaging may require additional testing.

B2B Procurement Guide

Bulk procurement of rosiglitazone requires verification of supplier credentials, including GMP certification and regulatory compliance (e.g., FDA, EMA). Key considerations include batch-to-batch consistency, impurity profiles, and documentation of stability testing. Large-scale buyers should negotiate contracts with clauses for quality audits and recall protocols. Pricing varies significantly by volume and geographic market, with reference ranges of $500-$2,000 per kilogram for active pharmaceutical ingredient (API). Lead times average 4-8 weeks for standard orders. Importers must ensure compliance with local regulations, as some countries restrict rosiglitazone distribution due to safety concerns.